


Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/881,204
				Filing Date	June 15, 2001
				First Named Inventor	Dominko et al.
				Group Art Unit	163T/1632
				Examiner Name	Ton, Thai-An N.
				Attorney Docket Number	10758.105001
Sheet	1	of	1		

RECEIVED
DEC 03 2003
TECHNICAL SERVICES
1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T 6
TNT	AA	Bunn, C.L. and Eisenstadt, J.M., <i>Cybrid Formation in Mouse L Cells : The Influence of Cytoplasmic-to-Cell Ration</i> , Somatic Cell Genetics, Vol. 3, No. 3, 1977, pp. 335-341		
	AB	Gopalakrishnan, T.V. and Anderson, W. French, <i>Epigenetic Activation of Phenylalanine Hydroxylase in Mouse Erythroleukemia Cells by the Cytoplasm of Rat Hepatoma Cells</i> , Proc. Natl. Acad. Sci. USA Vol. 76, No. 8, pp. 3932-2936, August 1979 Cell Biology		
	AC	Iwakura, Yoichiro, et al., <i>Pleiotropic Phenotypic Expression in Cybrids Derived from Mouse Teratocarcinoma Cells Fused With Rat Myoblast Cytoplasts</i> , Cell, Vol. 43, December 1985 (part 2) pp. 777-791		
	AD	Lucas, Joseph J. and Kates, Joseph R., <i>The Construction of Viable Nuclear-Cytoplasmic Hybrid Cells by Nuclear Transplantation</i> , Cell, Vol. 7, March 1976, pp. 397-405		
	AE	Tsukada, Y., et al., <i>Protein Synthesis and Tumorigenicity of the Cytoplasmic Hybrid Between Rat Yolk SAC Tumor and mouse Fibroblastic Cell Line</i>		
	AF	Watanabe, Toshio, et al., <i>Induction of Erythroid Differentiation by Cytoplasm Fusion in Mouse Erythroleukemia (Friend) Cells</i> , Experimental Cell Research 159 (1985) pp. 224-234		
	AG	Yatscoff, Randall W., et al., <i>Cybrid Formation with Recipient Cell Lines Containing Dominant Phenotypes</i> , Somatic Cell Genetics, Vol. 7, No. 1, 1981, pp. 1-9		
	AH	Zakhartchenko V et al. <i>Karyoplast-cytoplasm volume ratio in bovine nuclear transfer embryos: effect on developmental potential</i> . Mol Reprod Dev. Vol. 48 No. 3 1997, pp. 332-8.		
TNT	AI	Ziegler, Michael L., <i>Phenotypes Expression of Malignancy in Hybrid and Cybrid Mouse Cells</i> , Somatic Cell Genetics, Vol. 4, No. 4, 1978, pp. 477-489		

Examiner Signature	<i>Theresa G</i>	Date Considered	2/12/04
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.